For years, $7.2B in U.S. government-backed neuroperformance research sat untouched—proven cognitive enhancements with no commercial application.
David Bach saw the gap. Optios is bridging classified IP with market demand, transforming military-grade neuroscience into real-world performance gains.
The upside? Monumental. The imbalance? Even bigger.
We dive into:
• how declassified DOD research is unlocking a new frontier in neurotech
• the hidden psychology behind winning investor buy-in
• what $600M+ in exits taught him about product-market fit
Connect with us here:
1. David Bach:https://www.linkedin.com/in/david-bach-md-0b81b29/
2. George Bandarian:https://www.linkedin.com/in/georgebandarian/
3. Untapped Ventures:https://www.linkedin.com/company/untappedventures
00:00 Trailer
01:20 Introduction
01:46 David Bach
04:46 Journey to Harvard
10:26 Founding Optios
16:08 Tech Transfer and Market Research
22:09 The Future of Neuro-Performance
28:33 Key Lessons for Founders
33:34 Fundraising Insights
37:29 Closing Thoughts